Although no significant difference was observed across groups in the MSKCC skcm cohort treated with anti-CTLA-4 drug or the GSE78220 melanoma treated with anti-PD-1 drug, patients with high prognostic scores showed a tendency of short-term OS (Figures 2G,H). This evidence concerns the gene CTLA4 and melanoma.